TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster Randomized Trial of a Goal-Setting Intervention With Performance Feedback Reports Regarding Diabetes and Coronary Artery Disease for Family Physicians in Ontario
Brief Summary: There remains a large gap between ideal and actual care provided to patients with chronic diseases. Performance feedback reports are often used as a foundation for quality improvement interventions. There have been hundreds of trials investigating the use of feedback reports; the important question to ask now is not whether performance feedback reports can help to improve quality of care, but how to optimize feedback interventions to accomplish that goal. The purpose of this study is to test whether a theory-based intervention added to feedback reports sent to primary care providers can result in improved outcomes for patients with chronic disease.


Options:
A: Arm Label: Feedback report only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Goal-Setting Worksheet; Type: EXPERIMENTAL; Interventions: Other: Worksheet to facilitate goal-setting and action plans | Intervention Type: OTHER; Name: Worksheet to facilitate goal-setting and action plans; Assigned to Arm(s): Goal-Setting Worksheet
B: Arm Label: MD-C/PT-C; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MD-I/PT-C; Type: EXPERIMENTAL; Interventions: Behavioral: MD CQI-type intervention | Arm Label: MD-C/Pt-I; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle interventions to lower blood pressure for patients | Arm Label: MD-I/Pt-I; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle interventions to lower blood pressure for patients, Behavioral: MD CQI-type intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle interventions to lower blood pressure for patients; Assigned to Arm(s): MD-C/Pt-I, MD-I/Pt-I | Intervention Type: BEHAVIORAL; Name: MD CQI-type intervention; Assigned to Arm(s): MD-I/PT-C, MD-I/Pt-I
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Expanded Chronic Care Model | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Expanded Chronic Care Model; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Education for professionals; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Distribution of educational materials; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Feedback for professionals; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Reminders for professionals; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK2340272A) in the United Kingdom (UK)
Brief Summary: The focus of this study is to assess the safety of GSK's H1N1 vaccine in real life conditions as soon as the vaccine is used, in a mass vaccination programme, and with a system for rapid generation, communication and evaluation of safety data.

This study is a commitment to the European Medicines Agency (EMEA), as part of GlaxoSmithKline Biologicals' (GSK Biologicals') risk management plan for pandemic influenza vaccination.


Options:
A: Arm Label: 6-23 months; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 2-8 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 9-17 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 18-44 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 45-60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: >60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Intervention Type: OTHER; Name: This is non-intervention observational study; Assigned to Arm(s): 18-44 years, 2-8 years, 45-60 years, 6-23 months, 9-17 years, >60 years
B: Intervention Type: BIOLOGICAL; Name: Influenza vaccine; Assigned to Arm(s): N/A
C: Arm Label: FluBlok; Type: EXPERIMENTAL; Interventions: Biological: FluBlok Influenza Vaccination | Arm Label: TIV (Fluzone); Type: ACTIVE_COMPARATOR; Interventions: Biological: TIV (Fluzone) Influenza Vaccination | Intervention Type: BIOLOGICAL; Name: FluBlok Influenza Vaccination; Assigned to Arm(s): FluBlok | Intervention Type: BIOLOGICAL; Name: TIV (Fluzone) Influenza Vaccination; Assigned to Arm(s): TIV (Fluzone)
D: Arm Label: Total vaccinated cohort; Type: N/A; Interventions: Other: Safety follow up | Intervention Type: OTHER; Name: Safety follow up; Assigned to Arm(s): Total vaccinated cohort

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Prophylactic Ibuprofen Versus Placebo on Pain Relief and Success Rates of Medical Abortion: A Double-blind Randomized Placebo Controlled Study
Brief Summary: In the current study, we want to evaluate the prophylactic use of ibuprofen versus a placebo for medical abortion by mifepristone and misoprostol, at a gestational age of up to 7 weeks, in regard to the effect on pain relief and the overall procedure success.

expected results:

The prophylactic use of NSAIDs could offer significant pain relief and thereby a reduction in the need for additional pain relievers compared to the placebo, without interfering with the outcome of medical abortion


Options:
A: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Therapeutic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: Prophylactic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Prophylactic, Therapeutic
C: Arm Label: Mifepristone at home 24 hours before miso dosing starts; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: Mifepristone and first dose of misoprostol simultaneously.; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Mifepristone at home 24 hours before miso dosing starts | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Mifepristone and first dose of misoprostol simultaneously.
D: Arm Label: ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Single-Masked Clinical Trial Testing the Effect of Non-surgical Periodontal Therapy on Glycosylated Hemoglobin (HbA1c) Levels in Subjects With Type 2 Diabetes and Chronic Periodontitis
Brief Summary: The primary aim of the study is to determine if non-surgical periodontal therapy (scaling and root planing and supportive periodontal therapy) is efficacious compared to delayed therapy in reducing elevated glycosylated hemoglobin (HbA1c) at 6 months post-randomization in subjects with type 2 diabetes and untreated, moderate to advanced chronic periodontitis.

The secondary aims of the study are to:

1. evaluate whether 6 month (or shorter-term (3 month)) changes in clinical measures of chronic periodontitis (gingival index, bleeding on probing, probing depth, clinical attachment level) are related to changes in HbA1c and fasting glucose or insulin resistance as measured by the Homeostasis Model Assessment 2 (HOMA2).
2. assess the 3 month and 6 month efficacy of periodontal therapy on all of the above study outcomes. If a treatment response is observed for any of the study outcomes at 3 months, then the trial can evaluate whether this response is sustained at 6 months.


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Procedure: non-surgical periodontal treatment | Arm Label: control; Type: OTHER; Interventions: Procedure: non-surgical periodontal treatment | Intervention Type: PROCEDURE; Name: non-surgical periodontal treatment; Assigned to Arm(s): control, treatment
B: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Procedure: Periodontal Scaling and root planing | Intervention Type: PROCEDURE; Name: Periodontal Scaling and root planing; Assigned to Arm(s): intervention
C: Arm Label: Nonsurgical periodontal therapy; Type: EXPERIMENTAL; Interventions: Procedure: Nonsurgical periodontal therapy, Procedure: Oral hygiene instructions | Arm Label: Oral hygiene instructions; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Oral hygiene instructions | Intervention Type: PROCEDURE; Name: Nonsurgical periodontal therapy; Assigned to Arm(s): Nonsurgical periodontal therapy | Intervention Type: PROCEDURE; Name: Oral hygiene instructions; Assigned to Arm(s): Nonsurgical periodontal therapy, Oral hygiene instructions
D: Arm Label: Non-surgical periodontal therapy; Type: EXPERIMENTAL; Interventions: Procedure: Non-surgical periodontal therapy | Arm Label: Delayed non-surgical periodontal therapy; Type: OTHER; Interventions: Other: Delayed non-surgical periodontal therapy | Intervention Type: PROCEDURE; Name: Non-surgical periodontal therapy; Assigned to Arm(s): Non-surgical periodontal therapy | Intervention Type: OTHER; Name: Delayed non-surgical periodontal therapy; Assigned to Arm(s): Delayed non-surgical periodontal therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Remote Ischemic Preconditioning on Mortality and Morbidity in Cardiac Surgery: a Randomized Controlled Trial
Brief Summary: Perioperative myocardial injury is a serious complication of cardiac surgery. This complication increases both mortality and morbidity of cardiac surgery. Remote ischemic preconditioning (RIPC) is the concept that brief ischemia followed by reperfusion in an organ can reduce subsequent ischemia-reperfusion injury in distant organs. Recent several clinical trials showed powerful myocardial protective effect of remote ischemic preconditioning by reducing postoperative cardiac enzymes. However, the evidence that remote ischemic preconditioning can improve the clinical outcomes such as mortality and morbidity, is still lacking. The investigators perform a multicenter randomized controlled study to evaluate that remote ischemic preconditioning can improve the outcomes of cardiac surgery.


Options:
A: Arm Label: bilateral limb ischemic preconditioning (BLIPC); Type: EXPERIMENTAL; Interventions: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: bilateral limb ischemic preconditioning (Doctormate, IPC-906X); Assigned to Arm(s): bilateral limb ischemic preconditioning (BLIPC)
B: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: placebo remote ischemic preconditioning; Type: SHAM_COMPARATOR; Interventions: Procedure: sham remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: sham remote ischemic preconditioning; Assigned to Arm(s): placebo remote ischemic preconditioning
C: Arm Label: Remote ischemic preconditioning (RIPC); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischemic preconditioning (RIPC) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Placebo | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning (RIPC); Assigned to Arm(s): Remote ischemic preconditioning (RIPC) | Intervention Type: PROCEDURE; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Remote Ischemic Preconditioning on Mortality and Morbidity in Cardiac Surgery: a Randomized Controlled Trial
Brief Summary: Perioperative myocardial injury is a serious complication of cardiac surgery. This complication increases both mortality and morbidity of cardiac surgery. Remote ischemic preconditioning (RIPC) is the concept that brief ischemia followed by reperfusion in an organ can reduce subsequent ischemia-reperfusion injury in distant organs. Recent several clinical trials showed powerful myocardial protective effect of remote ischemic preconditioning by reducing postoperative cardiac enzymes. However, the evidence that remote ischemic preconditioning can improve the clinical outcomes such as mortality and morbidity, is still lacking. The investigators perform a multicenter randomized controlled study to evaluate that remote ischemic preconditioning can improve the outcomes of cardiac surgery.


Options:
A: Arm Label: Flavanol rich cocoa; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Arm Label: flavanol poor cocoa drink; Type: EXPERIMENTAL; Interventions: Other: Cocoa | Intervention Type: OTHER; Name: Cocoa; Assigned to Arm(s): Flavanol rich cocoa, flavanol poor cocoa drink
B: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control | Arm Label: Remote ischaemic conditioning; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Remote ischaemic preconditioning | Intervention Type: PROCEDURE; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Remote ischaemic conditioning | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control
D: Arm Label: Group 1 Control (65 patients); Type: SHAM_COMPARATOR; Interventions: Drug: IV Normal saline | Arm Label: Group 2 (65 patients); Type: ACTIVE_COMPARATOR; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Normal saline | Arm Label: Group 3 GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Drug: IV Glyceryl trinitrate 2-5ml/h | Arm Label: • Group 4 RIPC+GTN (65 patients):; Type: EXPERIMENTAL; Interventions: Other: Remote ischaemic preconditioning, Drug: IV Glyceryl trinitrate 2-5ml/h | Intervention Type: OTHER; Name: Remote ischaemic preconditioning; Assigned to Arm(s): Group 2 (65 patients), • Group 4 RIPC+GTN (65 patients): | Intervention Type: DRUG; Name: IV Normal saline; Assigned to Arm(s): Group 1 Control (65 patients), Group 2 (65 patients) | Intervention Type: DRUG; Name: IV Glyceryl trinitrate 2-5ml/h; Assigned to Arm(s): Group 3 GTN (65 patients):, • Group 4 RIPC+GTN (65 patients):

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Remote Ischemic Preconditioning on Mortality and Morbidity in Cardiac Surgery: a Randomized Controlled Trial
Brief Summary: Perioperative myocardial injury is a serious complication of cardiac surgery. This complication increases both mortality and morbidity of cardiac surgery. Remote ischemic preconditioning (RIPC) is the concept that brief ischemia followed by reperfusion in an organ can reduce subsequent ischemia-reperfusion injury in distant organs. Recent several clinical trials showed powerful myocardial protective effect of remote ischemic preconditioning by reducing postoperative cardiac enzymes. However, the evidence that remote ischemic preconditioning can improve the clinical outcomes such as mortality and morbidity, is still lacking. The investigators perform a multicenter randomized controlled study to evaluate that remote ischemic preconditioning can improve the outcomes of cardiac surgery.


Options:
A: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): N/A
C: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIPC, Drug: isoflurane+sufentanil anesthesia | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control, Drug: isoflurane+sufentanil anesthesia | Intervention Type: PROCEDURE; Name: RIPC; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: isoflurane+sufentanil anesthesia; Assigned to Arm(s): Control, RIPC
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Procedure: remote ischemic postconditioning | Intervention Type: PROCEDURE; Name: remote ischemic postconditioning; Assigned to Arm(s): 1, 2, 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation
Brief Summary: This open-label, comparative study will compare the efficacy, safety, and acceptability of 200 mg mifepristone followed in 24-48 hours by 800mcg buccal misoprostol or 400mcg sublingual misoprostol for termination of pregnancy in existing outpatient early medical abortion services among women 57-63 days' versus 64-70 days' gestation.


Options:
A: Arm Label: Buccal; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Arm Label: Sublingual; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Buccal, Sublingual | Intervention Type: DEVICE; Name: Semi-quantitative pregnancy test; Assigned to Arm(s): Buccal, Sublingual
B: Arm Label: Duo test; Type: OTHER; Interventions: Other: Self assessment | Arm Label: Routine follow up; Type: OTHER; Interventions: Other: Routine assessment | Intervention Type: OTHER; Name: Self assessment; Assigned to Arm(s): Duo test | Intervention Type: OTHER; Name: Routine assessment; Assigned to Arm(s): Routine follow up
C: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
D: Arm Label: 64-70 days' gestational age; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone and misoprostol | Arm Label: 57-63 days' gestational age; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Mifepristone and misoprostol; Assigned to Arm(s): 64-70 days' gestational age

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Conventional Versus Point-of-care Based Coagulation Management in Cardiac Surgery Patients Suffering From Increased Bleeding Tendency - a Prospective and Randomized Study
Brief Summary: The purpose of the study is to determine the efficacy of two different algorithms for coagulation management in patients undergoing cardiac surgery suffering from increased bleeding tendency. Algorithm 1 is based on conventional coagulation analyses (INR, aPTT, platelet count, fibrinogen concentration,...) and Algorithm 2 is based on thrombelastometry using the ROTEM-device and impedance aggregometry using the Multiplate device.


Options:
A: Arm Label: Fibrinogen if FibTEM < 8 mm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Human fibrinogen concentrate | Arm Label: Fibrinogen if FibTEM < 13 mm; Type: EXPERIMENTAL; Interventions: Drug: Human fibrinogen concentrate | Intervention Type: DRUG; Name: Human fibrinogen concentrate; Assigned to Arm(s): Fibrinogen if FibTEM < 13 mm, Fibrinogen if FibTEM < 8 mm
B: Arm Label: Clopidogrel+Aspirin, hypercoagulabel; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel+acetylsalicylic acid | Arm Label: Aspirin,hypercoagulabel control; Type: ACTIVE_COMPARATOR; Interventions: Drug: acetylsalicylic acid | Intervention Type: DRUG; Name: Clopidogrel+acetylsalicylic acid; Assigned to Arm(s): Clopidogrel+Aspirin, hypercoagulabel | Intervention Type: DRUG; Name: acetylsalicylic acid; Assigned to Arm(s): Aspirin,hypercoagulabel control
C: Arm Label: POC algorithm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Point-of-Care versus conventional coagulation management | Arm Label: conventional algorithm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Point-of-Care versus conventional coagulation management | Intervention Type: PROCEDURE; Name: Point-of-Care versus conventional coagulation management; Assigned to Arm(s): POC algorithm, conventional algorithm
D: Arm Label: coronary artery disease; Type: N/A; Interventions: N/A

Answer: C